On Thursday, Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)’s shares declined -1.14% to $188.83.
Alexion Pharmaceuticals, Inc. (ALXN) declared financial results for the second quarter of 2015. Net product sales of Soliris® (eculizumab) grew to $636 million, a 24% enhance, contrast to $512.5 million for the same period in 2014, despite currency headwinds. Non-GAAP diluted earnings per share (EPS) for the second quarter of 2015 were $1.44, contrast to $1.12 in the second quarter of 2014. On a GAAP basis, diluted EPS for the second quarter of 2015 was $0.83 per share, influenced by $40.1 million, or $0.20 per share, related to acquisition and restructuring costs resulting from the Synageva acquisition, contrast to $0.83 in the second quarter of 2014.
Second Quarter 2015 Financial Highlights
- Net product sales of Soliris®were $636 million contrast to $512.5 million in the same quarter last year.
- Non-GAAP R&D expense was $116.6 million contrast to $85.1 million in the same quarter last year. GAAP R&D expense was $131.7 million contrast to $92.6 million in the same quarter last year.
- Non-GAAP SG&A expense was $169.1 million contrast to $139.5 million in the same quarter last year. GAAP SG&A expense was $221.4 million contrast to $159.5 million in the same quarter last year.
- Non-GAAP effective tax rate was a benefit of 0.6% contrast to tax expense of 8.0% in the same quarter last year. In Q2 2015, the Company benefitted from the utilization of operating losses from Synageva in 2015.
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for the treatment of PNH and aHUS registry; Phase III clinical trials for the treatment of delayed kidney transplant graft function and myasthenia gravis; and Phase II clinical trials for the treatment of antibody mediated rejection in presensitized kidney transplant patients and neuromyelitis optica. In addition, it develops Asfotase alfa, a targeted enzyme replacement therapy that is under Phase II clinical trial for the treatment of metabolic disorders, counting hypophosphatasia; ALXN 1007, a novel humanized antibody in Phase II clinical trials for the treatment of anti-phospholipid syndrome and graft as compared to host disease; and cPMP (ALXN 1101) that is in Phase II trial for treating metabolic disorders.
Store Capital Corp (NYSE:STOR)’s shares gained 2.01% to $21.78.
Store Capital Corp (STOR) an internally managed net-lease real estate investment trust (REIT) that invests in Single Tenant Operational Real Estate, declared recently that it has accomplished its follow-on public offering of 11,562,500 shares of common stock sold by the Company and 9,712,500 shares of common stock sold by the selling stockholder, counting 2,775,000 shares of common stock sold by the selling stockholder in connection with the full exercise of the underwriters’ option to purchase additional shares, at a public offering price of $20.25.
Goldman, Sachs & Co., Credit Suisse and Morgan Stanley acted as joint book-running managers for the offering. BMO Capital Markets, Citigroup, KeyBanc Capital Markets and Wells Fargo Securities acted as joint lead managers for the offering; and Baird, Cowen and Company, Ladenburg Thalmann & Co. Inc., Raymond James, Stifel and SunTrust Robinson Humphrey acted as co-managers for the offering.
STORE Capital is a privately owned real estate investment trust. The firm invests in the real estate markets. It primarily invests in single-tenant properties counting chain restaurants, supermarkets, drugstores and other retail, service and distribution facilities. STORE Capital is based in Scottsdale, Arizona.
At the end of Thursday’s trade, Endeavour Silver Corp (NYSE:EXK)‘s shares dipped -6.84% to $1.77.
Endeavour Silver Corp.(EXK) posted steady silver production results in the Second Quarter, 2015 from the Company’s three operating silver mines in Mexico: the Guanaceví mine in Durango State and the Bolañitos and El Cubo mines in Guanajuato State.
Silver production in the Second Quarter, 2015 was on plan for the year at 1,769,741 ounces (oz) and gold production was 13,047 oz, slightly below plan. Silver equivalent production was also on plan at 2.7 million oz using a 70:1 silver gold ratio.
Production Highlights for Second Quarter, 2015 (Contrast to Second Quarter, 2014)
- Silver production raised 6% to 1,769,741 oz.
- Gold production reduced 14% to 13,047 oz.
- Silver equivalent production reduced 2% to 2.7 million oz (at a 70:1 silver: gold ratio).
- Silver oz sold up 8% to 1,912,595 oz.
- Gold oz sold down 6% to 13,797 oz.
Endeavour Silver Corp., a Canadian mineral company, engages in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. It produces silver-gold from its underground mines. The company primarily holds interests in the Guanacevi mine in the Durango state; and the Bolañitos and El Cubo mines in the Guanajuato state of Mexico. It also has interests in various exploration properties in Mexico and Chile, counting Guadalupe Y Calvo and La Bufa exploration projects in Chihuahua, Mexico; and the San Sebastian project located in Jalisco, Mexico, in addition to options to acquire a 51% interest in the Panuco exploration property located in Durango, Mexico; and purchase a 75% interest in the El Inca properties located in Chile.
Weight Watchers International, Inc. (NYSE:WTW), ended its Thursday’s trading session with -2.88% loss, and closed at $6.08.
Weight Watchers International, Inc. (WTW) declared its results for the second quarter of fiscal 2015 and raised its full year fiscal 2015 earnings guidance.
- Q2 2015 revenues were $309.8 million, down 22.1% (16.5% on a constant currency basis) as compared to the preceding year period, with total paid weeks down 17.6%.
- Q2 2015 earnings per fully diluted share (EPS) was $0.49; not taking into account the benefit of $0.07 per fully diluted share from the early extinguishment of debt, Q2 2015 adjusted EPS was $0.42.
- The Company raised its full year fiscal 2015 earnings guidance to between $0.57 and $0.72 per fully diluted share on an adjusted basis.
- Following a debt tender offer, the Company made a cash payment of $77.2 million to prepay $84.9 million of its debt obligations maturing in April 2016.
Weight Watchers International, Inc. provides weight administration services worldwide. The company operates through North America, United Kingdom, Continental Europe, and Other segments. It offers a range of products and services comprising nutritional, exercise, and behavioral tools and approaches.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
